Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer

被引：0

作者：

Valiente, Consolacion Molto ^{[1
,2
]}

Amir, Eitan ^{[1
,2
,3
,4
]}

机构：

[1] Princess Margaret Canc Ctr, Dept Med, Div Med Oncol & Hematol, Toronto, ON, Canada

[2] Univ Toronto, Toronto, ON, Canada

[3] Princess Margaret Canc Ctr, Dept Med, Div Med Oncol & Hematol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada

[4] Univ Toronto, 610 Univ Ave, Toronto, ON M5G 2M9, Canada

来源：

TRANSLATIONAL CANCER RESEARCH | 2023年 / 12卷 / 07期

关键词：

Metastatic breast cancer; triple negative; PARP inhibitors; BRCAness; BRCA-like phenotype; AMERICAN SOCIETY; CLINICAL BENEFIT; DOUBLE-BLIND; FRAMEWORK; OLAPARIB; MAGNITUDE; VELIPARIB; MUTATION; PLACEBO; PHASE-2;

D O I：

10.21037/tcr-23-365

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1887 / 1890

页数：4

共 21 条

[1] Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use [J].

Abbotts, Rachel ;

Dellomo, Anna J. ;

Rassool, Feyruz, V .

CANCERS, 2022, 14 (11)

[2] BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside [J].

Boussios, Stergios ;

Rassy, Elie ;

Moschetta, Michele ;

Ghose, Aruni ;

Adeleke, Sola ;

Sanchez, Elisabet ;

Sheriff, Matin ;

Chargari, Cyrus ;

Pavlidis, Nicholas .

CANCERS, 2022, 14 (16)

[3] A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) [J].

Cherny, N. I. ;

Sullivan, R. ;

Dafni, U. ;

Kerst, J. M. ;

Sobrero, A. ;

Zielinski, C. ;

de Vries, E. G. E. ;

Piccart, M. J. .

ANNALS OF ONCOLOGY, 2015, 26 (08) :1547-1573

[4] Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score [J].

Cherny, Nathan I. ;

de Vries, Elisabeth G. E. ;

Dafni, Urania ;

Garrett-Mayer, Elizabeth ;

McKernin, Shannon E. ;

Piccart, Martine ;

Latino, Nicola J. ;

Douillard, Jean-Yves ;

Schnipper, Lowell E. ;

Somerfield, Mark R. ;

Bogaerts, Jan ;

Karlis, Dimitris ;

Zygoura, Panagiota ;

Vervita, Katerina ;

Pentheroudakis, George ;

Tabernero, Josep ;

Zielinski, Christoph ;

Wollins, Dana S. ;

Schilsky, Richard L. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04) :336-+

[5] Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer [J].

Cortes, J. ;

Rugo, H. S. ;

Cescon, D. W. ;

Im, S-A ;

Yusof, M. M. ;

Gallardo, C. ;

Lipatov, O. ;

Barrios, C. H. ;

Perez-Garcia, J. ;

Iwata, H. ;

Masuda, N. ;

Otero, M. Torregroza ;

Gokmen, E. ;

Loi, S. ;

Guo, Z. ;

Zhou, X. ;

Karantza, V ;

Pan, W. ;

Schmid, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (03) :217-226

[6] BRCAness: a deeper insight into basal-like breast tumors [J].

De Summa, S. ;

Pinto, R. ;

Sambiasi, D. ;

Petriella, D. ;

Paradiso, V. ;

Paradiso, A. ;

Tommasi, S. .

ANNALS OF ONCOLOGY, 2013, 24 :13-21

[7] Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer [J].

Desnoyers, A. ;

Nadler, M. ;

Wilson, B. E. ;

Stajer, S. ;

Amir, E. .

NPJ BREAST CANCER, 2022, 8 (01)

[8] Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Dieras, Veronique ;

Han, Hyo S. ;

Kaufman, Bella ;

Wildiers, Hans ;

Friedlander, Michael ;

Ayoub, Jean-Pierre ;

Puhalla, Shannon L. ;

Bondarenko, Igor ;

Campone, Mario ;

Jakobsen, Erik H. ;

Jalving, Mathilde ;

Oprean, Cristina ;

Palacova, Marketa ;

Park, Yeon Hee ;

Shparyk, Yaroslav ;

Yanez, Eduardo ;

Khandelwal, Nikhil ;

Kundu, Madan G. ;

Dudley, Matthew ;

Ratajczak, Christine K. ;

Maag, David ;

Arun, Banu K. .

LANCET ONCOLOGY, 2020, 21 (10) :1269-1282

[9] American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes [J].

Ellis, Lee M. ;

Bernstein, David S. ;

Voest, Emile E. ;

Berlin, Jordan D. ;

Sargent, Daniel ;

Cortazar, Patricia ;

Garrett-Mayer, Elizabeth ;

Herbst, Roy S. ;

Lilenbaum, Rogerio C. ;

Sima, Camelia ;

Venook, Alan P. ;

Gonen, Mithat ;

Schilsky, Richard L. ;

Meropol, Neal J. ;

Schnipper, Lowell E. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (12) :1277-+

[10] Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study [J].

Gelmon, Karen A. ;

Tischkowitz, Marc ;

Mackay, Helen ;

Swenerton, Kenneth ;

Robidoux, Andre ;

Tonkin, Katia ;

Hirte, Hal ;

Huntsman, David ;

Clemons, Mark ;

Gilks, Blake ;

Yerushalmi, Rinat ;

Macpherson, Euan ;

Carmichael, James ;

Oza, Amit .

LANCET ONCOLOGY, 2011, 12 (09) :852-861

← 1 2 3 →